DISCLAIMER:
- I am NOT an analyst or employed by a broker
- Following is my view which may diametrically be opposite that of someone else's. Hence, please take the following recommendations with huge rock of salt and do your due diligence
- Following is my watchlist and I may hold/invest in near future in one or more of the following. All I am doing is capturing my current thought process.
--------------------------------------------------------------------------------------
Recommendations:
****************
CIPLA:
- Debt / Equity Ratio - NIL
- RONW: consistently above 20% over last 5 years which is excellent
- Dividend Payout: Consistent over past few years
- PE in line with industry expectations - Pricing is fair from this perspective
- P/Bv - 4.55 - BV growing steadily over last 4 years
- POrtfolio is wide ranging from prescription products to Off the counter (OTC) to Animal Products to Flavors and Fragnances which is pretty diversified
TORRENT PHARMA:
- Debt / Equity Ratio - 0.6
- P/BV - 5.57
- PE is 16.86 much lower compared to indsutry PE
- Dividend Yield is very consistent and pretty good
- EPS and BV have grown consistently over last 5 years
- RONNW: Average of 20+% over past few years
- Leader in Cardio Vascular and CNS threauptic areas - Markets in India and US
ORCHID CHEMICALS:
- Debt / Equity Ratio: 1.63 (high)
- P/BV - 2.07
- PE is 4.21 very very low compared to industry PE
- Dividend yield is one of the highest in the industry
- Recently completed a huge transaction - I presume it was takeover and has turned positive very quickly
- Reference:
http://www.thehindu.com/business/companies/article1103096.ece
BIOCON:
- Debt/Equity Ratio: 0.12
- produces agents/intermediaries - Working on oral insulin which can be huge hit in future
Happy Investing !!